(3R,4R)-4-Thiazol-2-yl-3-triisopropylsilanyloxy-azetidin-2-one | 722492-27-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (3R,4R)-4-Thiazol-2-yl-3-triisopropylsilanyloxy-azetidin-2-one
• CAS: 722492-27-5
• 化学式: C₁₅H₂₆N₂O₂SSi
• 分子量: 326.535
• InChiKey: YVWRKKLQXIPLQL-CHWSQXEVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.87
• 重原子数：
  21.0
• 可旋转键数：
  6.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  51.22
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  (3R,4R)-4-Thiazol-2-yl-3-triisopropylsilanyloxy-azetidin-2-one 在 4-二甲氨基吡啶 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 生成 C₅₂H₇₄N₂O₁₃SSi
  参考文献：
  名称：

  New highly active taxoids from 9β-dihydrobaccatin-9,10-acetals. Part 5

  摘要：

  To improve the metabolic stability of 3, which exhibited both in vitro antitumor activity and in vivo efficacy by both iv and po administration, we designed and synthesized new taxane analogues. Most of the synthetic compounds maintained excellent antitumor activity and were scarcely metabolized by human liver microsomes. And some compounds exhibited potent antitumor effects against B16 melanoma BL6 in vivo by both iv and po administration similarly to 3. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.109
• 作为产物：
  描述：

  Acetic acid (3S,4S)-1-(4-methoxy-phenyl)-2-oxo-4-thiazol-2-yl-azetidin-3-yl ester 在 咪唑 、 甲醇 、 ammonium cerium(IV) nitrate 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 (3R,4R)-4-Thiazol-2-yl-3-triisopropylsilanyloxy-azetidin-2-one
  参考文献：
  名称：

  New highly active taxoids from 9β-dihydrobaccatin-9,10-acetals. Part 5

  摘要：

  To improve the metabolic stability of 3, which exhibited both in vitro antitumor activity and in vivo efficacy by both iv and po administration, we designed and synthesized new taxane analogues. Most of the synthetic compounds maintained excellent antitumor activity and were scarcely metabolized by human liver microsomes. And some compounds exhibited potent antitumor effects against B16 melanoma BL6 in vivo by both iv and po administration similarly to 3. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.109